Fouad Namouni compensation by year
Blueprint Medicines Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $583,694 | $642,879 | $671,809 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $919,650 | $967,578 | $2,649,360 |
| Option awards | $974,133 | $736,113 | $1,618,179 |
| Non-equity incentive | $332,705 | $453,230 | $544,165 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $1,978 | $13,800 |
| Total | $2,810,182 | $2,801,778 | $5,497,313 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Blueprint Medicines Corp DEF 14A filed April 24, 2025, accession 0001558370-25-005415, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Blueprint Medicines Corp filed document, accession 0001558370-25-005415. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 15,000 | $1,308,300 | — |
| RSU | 11,250 | $981,225 | — |
| PSU | 9,000 | $891,031 | — |
| PSU | 5,400 | $836,522 | — |
| RSU | 7,500 | $654,150 | — |
| RSU | 3,265 | $284,773 | — |
| Option | 16,875 | — | $43.15 |
| Option | 9,375 | — | $61.31 |
| Option | 1,633 | — | $100.13 |
| Option | 24,375 | — | $95.12 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Blueprint Medicines Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
9 Form 4 lines since the FY2024 proxy (filed April 24, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-07-17 | Disposition to the issuer derivative | — | 30,000 | — | 0 |
| 2025-07-17 | Disposition to the issuer derivative | — | 30,000 | — | 0 |
| 2025-07-17 | U | — | 31,956 | — | 0 |
| 2025-07-17 | Grant or award | — | 39,456 | — | 115,237 |
| 2025-07-17 | Disposition to the issuer | — | 83,281 | — | 31,956 |
| 2025-07-17 | Disposition to the issuer derivative | — | 26,125 | — | 0 |
| 2025-07-17 | Disposition to the issuer derivative | — | 30,000 | — | 0 |
| 2025-07-17 | Disposition to the issuer derivative | — | 26,400 | — | 0 |
The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Blueprint Medicines’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kathryn Haviland | President and Chief Executive Officer | $13,477,004 |
| Christina Rossi | Chief Operating Officer | $6,542,019 |
| Fouad Namouni · this page | President, Research and Development | $5,497,313 |
| Percy Carter | Chief Scientific Officer | $5,132,463 |
| Michael Landsittel | Chief Financial Officer | $4,191,251 |
Fouad Namouni's compensation dossier, Blueprint Medicines
You have read Fouad Namouni's totals and holdings. The dossier adds each equity grant Blueprint Medicines disclosed for Fouad Namouni and Blueprint Medicines's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Blueprint Medicines compensation record
free company briefThis page is one person within Blueprint Medicines's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Blueprint Medicines proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Blueprint Medicines's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Blueprint Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BPMC
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.